Publications

Spotlight Publication

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

European Society for Medical Oncology (ESMO) GI

Jun 28
- Jul 1, 2023
Results from an expanded phase 1 trial of botensilimab, a multifunctional anti-CTLA-4, plus balstilimab(anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer
Bullock, et al.

Filter by

AGEN2373 (CD137 Agonist)

Society for Immunotherapy of Cancer (SITC)

Nov 7
- Nov 11, 2018
AGEN2373 is a Conditionally-Active Agonist Antibody Targeting the Co-Stimulatory Receptor CD137 for the Treatment of Human Malignancies.
Galand, et al.
Balstilimab (PD-1 Antagonist)

European Society for Medical Oncology (ESMO)

Oct 19
- Oct 23, 2018
Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into Second-Line Cervical Cancer and Solid Tumors.
Coward, et al.
Zalifrelimab (CTLA-4 Antagonist)

European Society for Medical Oncology (ESMO)

Oct 19
- Oct 23, 2018
Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into Second-Line Cervical Cancer and Solid Tumors.
Coward, et al.
Balstilimab (PD-1 Antagonist)

European Society for Medical Oncology (ESMO)

Oct 19
- Oct 23, 2018
Phase 1/2, Open-Label, Multiple Ascending Dose Trial of AGEN2034, an Anti–PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation in Advanced Cancer and Expansion Cohorts in Subjects With Relapsed/Refractory Cervical Cancer.
Drescher, et al.
AGEN1327 (TIGIT Antagonist)

Cancer Cell

Jun 11, 2018
Selective FcgR Co-Engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.
Waight, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

Cancer Cell

Jun 11, 2018
Selective FcgR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.
Waight, et al.